• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

靶向衣壳蛋白组装与稳定性的抗HIV-1策略新进展

New Advances in Anti-HIV-1 Strategies Targeting the Assembly and Stability of Capsid Protein.

作者信息

Zhang Chengfeng, Li Benteng, Li Jiamei, Zhang Haihong, Wu Yuqing

机构信息

State Key Laboratory for Supramolecular Structure and Materials, College of Chemistry, Jilin University, No. 2699 Qianjin Street, Changchun 130012, China.

Institute of Theoretical Chemistry, College of Chemistry, Jilin University, No. 2 Liutiao Road, Changchun 130023, China.

出版信息

Int J Mol Sci. 2025 Jun 17;26(12):5819. doi: 10.3390/ijms26125819.

DOI:10.3390/ijms26125819
PMID:40565280
Abstract

The HIV-1 capsid has emerged as a highly attractive drug target due to its highly conserved sequence and critical role in the viral life cycle. By disrupting interactions between capsid proteins and impairing the proper assembly or disassembly of the capsid, the inhibitors can effectively suppress HIV-1 replication and infection. Based on this mechanism, numerous small-molecule agents targeting the HIV-1 capsid protein have been developed to date. In this review, we report the latest advances in such inhibitors and delve into their molecular mechanisms of action. We find a focus on small molecules modulating capsid stability and their assembly/disassembly. Hopefully this study will further enhance the understanding of HIV-1 inhibition mechanisms, facilitating the future exploration of novel capsid inhibitors.

摘要

由于HIV-1衣壳具有高度保守的序列以及在病毒生命周期中的关键作用,它已成为极具吸引力的药物靶点。通过破坏衣壳蛋白之间的相互作用并损害衣壳的正确组装或拆卸,抑制剂可有效抑制HIV-1的复制和感染。基于这一机制,迄今为止已开发出许多靶向HIV-1衣壳蛋白的小分子药物。在本综述中,我们报告了此类抑制剂的最新进展,并深入探讨了它们的分子作用机制。我们发现研究重点在于调节衣壳稳定性及其组装/拆卸的小分子。希望这项研究将进一步加深对HIV-1抑制机制的理解,促进未来新型衣壳抑制剂的探索。

相似文献

1
New Advances in Anti-HIV-1 Strategies Targeting the Assembly and Stability of Capsid Protein.靶向衣壳蛋白组装与稳定性的抗HIV-1策略新进展
Int J Mol Sci. 2025 Jun 17;26(12):5819. doi: 10.3390/ijms26125819.
2
Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults.成人慢性未抑制的HIV感染中的结构化治疗中断(STI)
Cochrane Database Syst Rev. 2006 Jul 19;2006(3):CD006148. doi: 10.1002/14651858.CD006148.
3
Ebselen, a Small-Molecule Capsid Inhibitor of HIV-1 Replication.依布硒啉,一种HIV-1复制的小分子衣壳抑制剂。
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2195-208. doi: 10.1128/AAC.02574-15. Print 2016 Apr.
4
HIV-1 Maturation: Lessons Learned from Inhibitors.HIV-1 成熟:抑制剂带来的启示。
Viruses. 2020 Aug 26;12(9):940. doi: 10.3390/v12090940.
5
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
6
Therapeutic drug monitoring of antiretrovirals for people with HIV.对感染艾滋病毒者的抗逆转录病毒药物进行治疗药物监测。
Cochrane Database Syst Rev. 2009 Jul 8(3):CD007268. doi: 10.1002/14651858.CD007268.pub2.
7
Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men.降低男男性行为者中艾滋病毒性传播风险的行为干预措施。
Cochrane Database Syst Rev. 2008 Jul 16(3):CD001230. doi: 10.1002/14651858.CD001230.pub2.
8
Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization.小分子通过破坏病毒衣壳抑制人类免疫缺陷病毒 1 型感染。
J Virol. 2011 Jan;85(1):542-9. doi: 10.1128/JVI.01406-10. Epub 2010 Oct 20.
9
HIV Genome-Wide Protein Associations: a Review of 30 Years of Research.HIV全基因组蛋白质关联:30年研究综述
Microbiol Mol Biol Rev. 2016 Jun 29;80(3):679-731. doi: 10.1128/MMBR.00065-15. Print 2016 Sep.
10
Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.用于治疗符合抗逆转录病毒治疗条件的孕妇艾滋病毒感染的抗逆转录病毒疗法。
Cochrane Database Syst Rev. 2010 Mar 17(3):CD008440. doi: 10.1002/14651858.CD008440.

本文引用的文献

1
Clinical Pharmacokinetics and Safety of a New HIV-1 Capsid Inhibitor, VH4004280, After Oral Administration in Adults Without HIV.新型HIV-1衣壳抑制剂VH4004280在未感染HIV的成年人口服后的临床药代动力学和安全性
Infect Dis Ther. 2025 Jun;14(6):1313-1326. doi: 10.1007/s40121-025-01154-x. Epub 2025 Apr 26.
2
Integrating different approaches for the identification of new disruptors of HIV-1 capsid multimerization.整合不同方法以鉴定HIV-1衣壳多聚化的新型干扰因子。
Biochem Biophys Res Commun. 2025 May 12;763:151572. doi: 10.1016/j.bbrc.2025.151572. Epub 2025 Mar 14.
3
Structural and mechanistic bases for resistance of the M66I capsid variant to lenacapavir.
M66I衣壳变体对来那卡韦耐药的结构和机制基础
mBio. 2025 May 14;16(5):e0361324. doi: 10.1128/mbio.03613-24. Epub 2025 Apr 15.
4
Lenacapavir for Human Immunodeficiency Virus (HIV) Prevention: A Commitment to Equitable Access and Partnership by Gilead Sciences.用于预防人类免疫缺陷病毒(HIV)的来那卡帕韦:吉利德科学公司对公平获取和合作的承诺。
Clin Infect Dis. 2025 Apr 9. doi: 10.1093/cid/ciaf116.
5
Quinazolinone-based Subchemotypes for Targeting HIV-1 Capsid Protein: Design and Synthesis.用于靶向HIV-1衣壳蛋白的喹唑啉酮类亚化学型:设计与合成
Med Chem Res. 2024 Dec;33(12):2431-2447. doi: 10.1007/s00044-024-03305-0. Epub 2024 Sep 15.
6
Clinical Pharmacokinetics and Safety of Orally Administered VH4011499, a New HIV-1 Capsid Inhibitor, in Adults Without HIV.新型HIV-1衣壳抑制剂VH4011499口服给药在未感染HIV的成人中的临床药代动力学和安全性
Infect Dis Ther. 2025 May;14(5):1011-1025. doi: 10.1007/s40121-025-01129-y. Epub 2025 Apr 2.
7
Lenacapavir disrupts HIV-1 core integrity while stabilizing the capsid lattice.来那卡帕韦破坏HIV-1核心完整性,同时稳定衣壳晶格。
Proc Natl Acad Sci U S A. 2025 Apr 8;122(14):e2420497122. doi: 10.1073/pnas.2420497122. Epub 2025 Apr 1.
8
Structural Virology: The Key Determinants in Development of Antiviral Therapeutics.结构病毒学:抗病毒治疗药物研发中的关键决定因素
Viruses. 2025 Mar 14;17(3):417. doi: 10.3390/v17030417.
9
Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study.每年一次注射用lenacapavir的药代动力学和安全性:一项1期开放标签研究。
Lancet. 2025 Apr 5;405(10485):1147-1154. doi: 10.1016/S0140-6736(25)00405-2. Epub 2025 Mar 11.
10
Human viruses: An ever-increasing list.人类病毒:种类不断增加。
Virology. 2025 Mar;604:110445. doi: 10.1016/j.virol.2025.110445. Epub 2025 Feb 2.